Kazia Therapeutics Limited announced a business update, reporting an initial immune-complete response (iCR) in a patient with stage IV triple-negative breast cancer (TNBC) under an FDA-authorized single-patient expanded access protocol. The patient was treated with a combination of paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy, resulting in a radiologic response per iRECIST criteria. The company noted that this outcome supports the mechanistic hypothesis for paxalisib in enhancing anti-tumor immunity when combined with checkpoint blockade. Kazia also announced the acceptance of two scientific presentations related to its paxalisib and NDL2 programs at the 2025 Brisbane Cancer Conference, scheduled for November 27-28, 2025. The NDL2 PD-L1 degrader program, developed in collaboration with QIMR Berghofer, is advancing toward IND-enabling studies anticipated in early 2026. The program targets resistant forms of the PD-L1 protein and aims to address resistance mechanisms to current checkpoint inhibitors. Additionally, Kazia reported progress in its glioblastoma (GBM) program, stating plans to request a FDA Type C Meeting following strong overall survival signals from paxalisib studies. The company also disclosed it had received notice from Nasdaq regarding non-compliance with the minimum market value of listed securities requirement, with a deadline of November 10, 2025, to regain compliance.